Antivirals, Blockbuster drugs, Drug costs, Drug development strategy, Geriatric disease, Immunoprophylaxis, Infectious disease, Pediatric disease, Respiratory disease, Respiratory syncytial virus, RSV, Synagis, Vaccines, Viral disease, Virus

Key Topics Covered:

Executive Summary

Strategic Considerations Stakeholder Implications Introduction

Disease Overview

Disease Description Disease Burden

Epidemiology

Overview Disease Defi nition Methods Analysis

Diagnosis

Current Interventions

Vaccines Immunoprophylaxis RespiGam Synagis Treatments Virazole/Virazide/Vilone The Upshot

Emerging Therapies

Vaccines Immunoprophylaxis Treatments

2010 Market and Outlook

Physicians and Patients Cost Considerations Study Trial or Design Treatment and Potential Sales

Bibliography

Companies Mentioned:

ADMA Biologics Alnylam Pharmaceuticals AlphaVax AmVac Antigenics Arrow Therapeutics AstraZeneca Bavarian Nordic Cubist Pharmaceuticals Functional Genetics GenVec Johnson & Johnson Kyowa Hakko Kirin MedImmune NanoBio Novartis NovaVax Pevion Biotech St. Jude Childrens' Research Hospital Symphogen Tibotec Trellis Bioscience

researchandmarkets